


## PHARMACEUTICAL 2019

## Immune Therapeutics Inc. Rank 337 of 371





## PHARMACEUTICAL 2019

## Immune Therapeutics Inc. Rank 337 of 371

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2,358% points. The greatest weakness of Immune Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 409% points.

The company's Economic Capital Ratio, given in the ranking table, is -829%, being 498% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	89
Cost of Goods Sold	48
Intangible Assets	0
Liabilities, Current	11,342
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	774
Other Liabilities	0
Other Net Income	-4,541
Property and Equipment	2.8
Research and Development	144
Revenues	114
Selling, General and Administrative Expense	3,232

Output Variable	Value in 1000 USD
Assets	92
Liabilities	11,342
Expenses	4,198
Stockholders Equity	-11,251
Net Income	-8,626
Comprehensive Net Income	-8,626
Economic Capital Ratio	-829%